| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | GPCR1; GPR86; GPR94; P2Y13; SP174; FKSG77 |
| Entrez GeneID | 53829 |
| WB Predicted band size | Calculated MW: 41 kDa; Observed MW: 41 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human P2Y13 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于P2Y13抗体的模拟参考文献(仅供示例参考，实际文献请通过学术数据库查询)：
---
1. **文献名称**: *Role of P2Y13 Receptor in Hepatic High-Density Lipoprotein Metabolism*
**作者**: Smith A, et al.
**摘要**: 本研究利用特异性P2Y13抗体，揭示了该受体在肝脏细胞中调控HDL胆固醇摄取的作用。实验显示，P2Y13基因敲除小鼠的HDL代谢异常，抗体染色证实其在肝细胞膜上的高表达。
2. **文献名称**: *Development of a Monoclonal Antibody Targeting Human P2Y13 Receptor for Neuroinflammatory Studies*
**作者**: Zhang L, et al.
**摘要**: 研究团队开发了一种高亲和力抗人P2Y13单克隆抗体，验证了其在小胶质细胞中的特异性结合能力。该抗体被用于流式细胞术和免疫组化，证实P2Y13在神经炎症中的表达上调。
3. **文献名称**: *P2Y13 Receptor Localization in Atherosclerotic Plaques: An Immunohistochemical Analysis*
**作者**: Patel R, et al.
**摘要**: 通过免疫组织化学技术结合P2Y13抗体，研究发现该受体在动脉粥样硬化斑块巨噬细胞中显著表达，提示其可能参与胆固醇沉积的调控通路。
4. **文献名称**: *Antibody-Based Blockade of P2Y13 Receptor Attenuates Fibrosis in Experimental Liver Disease*
**作者**: Kim H, et al.
**摘要**: 使用P2Y13中和抗体干预肝纤维化模型，结果显示受体抑制可减少胶原沉积，提示P2Y13可能成为肝纤维化的治疗靶点。
---
如需真实文献，建议通过PubMed、Web of Science或Google Scholar检索关键词“P2Y13 antibody”或“P2Y13 receptor”获取最新研究。
The P2Y13 receptor, a member of the purinergic receptor family, is a G protein-coupled receptor (GPCR) activated by extracellular nucleotides like ADP. It plays roles in various physiological processes, including cholesterol metabolism, platelet function, and neuroprotection. The P2Y13 antibody is a research tool developed to detect and study this receptor's expression, localization, and functional interactions.
P2Y13 antibodies are typically generated using synthetic peptides or recombinant protein fragments corresponding to specific extracellular or intracellular domains of the receptor. They enable techniques such as Western blotting, immunofluorescence, and flow cytometry to visualize P2Y13 in tissues or cell lines. Studies using these antibodies have highlighted the receptor's involvement in high-density lipoprotein (HDL) metabolism, particularly in hepatocytes, where it regulates reverse cholesterol transport. Dysregulation of P2Y13 signaling has been implicated in metabolic disorders, atherosclerosis, and cardiovascular diseases.
Recent research also explores P2Y13's potential in neuroinflammatory conditions and cancer progression. However, challenges remain in antibody specificity due to homology with other P2Y receptors. Validation via knockout controls or functional assays is critical. Overall, P2Y13 antibodies are vital for unraveling the receptor's pathophysiological roles and therapeutic targeting opportunities.
×
